Trust Company’s Exact Sciences EXAS Stock Holding History

Trust Company’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-100	Closed	-$1K	–	350
2016 Q4	$1K	Buy	+100	New	+$1.61K	﹤0.01%	357

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Trust Company's EXAS Position: Q1 2017 in Review

Trust Company sold out of Exact Sciences (EXAS) in Q1 2017, closing a stake of 100 shares — an estimated $1K sold.

Trust Company first reported a position in EXAS in Q4 2016 and held it in 1 quarter. The position peaked at $1K in Q4 2016. 224 funds tracked by Wall St. Rank hold EXAS as of Q1 2017.

Trust Company reported no remaining Exact Sciences position as of Q1 2017 after selling out during the quarter.
Trust Company sold 100 Exact Sciences shares in Q1 2017, an estimated $1K.
Trust Company first reported a position in Exact Sciences in Q4 2016 and held it in 1 quarter.
Trust Company's Exact Sciences position peaked at $1K in Q4 2016.
224 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2017.

Based on Trust Company's 13F filing for Q1 2017, filed 6 Apr 2017.